Verrica Pharmaceuticals Inc (VRCA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Verrica Pharmaceuticals Inc stock (VRCA) is currently trading at $4.62. Verrica Pharmaceuticals Inc PS ratio (Price-to-Sales) is 2.16. Analyst consensus price target for VRCA is $16.50. WallStSmart rates VRCA as Sell.
- VRCA PE ratio analysis and historical PE chart
- VRCA PS ratio (Price-to-Sales) history and trend
- VRCA intrinsic value — DCF, Graham Number, EPV models
- VRCA stock price prediction 2025 2026 2027 2028 2029 2030
- VRCA fair value vs current price
- VRCA insider transactions and insider buying
- Is VRCA undervalued or overvalued?
- Verrica Pharmaceuticals Inc financial analysis — revenue, earnings, cash flow
- VRCA Piotroski F-Score and Altman Z-Score
- VRCA analyst price target and Smart Rating
Verrica Pharmaceuticals Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Verrica Pharmaceuticals Inc (VRCA) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Verrica Pharmaceuticals Inc (VRCA) Key Strengths (1)
Revenue surging 1380.00% year-over-year
Supporting Valuation Data
Verrica Pharmaceuticals Inc (VRCA) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Micro-cap company with very limited liquidity and high volatility
Premium pricing at 3.8x book value
Revenue is fairly priced at 2.16x sales
Moderate institutional interest at 30.42%
Verrica Pharmaceuticals Inc (VRCA) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Revenue Growth. Growth metrics are encouraging with Revenue Growth at 1380.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Profit Margin. Some valuation metrics including Price/Sales (2.16), Price/Book (3.78) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -240.40%, Operating Margin at -136.40%, Profit Margin at -50.30%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -240.40% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1380.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VRCA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VRCA's Price-to-Sales ratio of 2.16x trades at a deep discount to its historical average of 9.84x (10th percentile). The current valuation is 92% below its historical high of 26.56x set in May 2024, and 135% above its historical low of 0.92x in Mar 2025. Over the past 12 months, the PS ratio has expanded from ~0.9x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Verrica Pharmaceuticals Inc (VRCA) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Verrica Pharmaceuticals Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 36M with 1380% growth year-over-year. The company is currently unprofitable, posting a -50.3% profit margin.
Key Findings
Revenue growing at 1380% YoY, reaching 36M. This pace significantly outperforms most BIOTECHNOLOGY peers.
Debt-to-equity ratio of -2.10 indicates a conservative balance sheet with 21M in cash.
The company is unprofitable with a -50.3% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -5M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Verrica Pharmaceuticals Inc maintain 1380%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Verrica Pharmaceuticals Inc.
Bottom Line
Verrica Pharmaceuticals Inc is a high-conviction growth story with revenue accelerating at 1380% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin -50.3% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Verrica Pharmaceuticals Inc(VRCA)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Verrica Pharmaceuticals Inc., a dermatological therapy company, develops and markets treatments for people with skin conditions in the United States. The company is headquartered in West Chester, Pennsylvania.